Collegium Pharmaceutical, Inc. Defined Contribution Plan, Cost
Collegium Pharmaceutical, Inc. (COLL) reported Defined Contribution Plan, Cost of $3.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-02-26
- Collegium Pharmaceutical, Inc. defined contribution plan, cost for fiscal 2025 was $3.46M, a 77.94% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. defined contribution plan, cost for fiscal 2024 was $1.95M, a 10.57% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. defined contribution plan, cost for fiscal 2023 was $1.76M, a 33.76% increase from fiscal 2022.
- Collegium Pharmaceutical, Inc. defined contribution plan, cost for fiscal 2022 was $1.31M, a 6.39% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $3.46M 10-K · filed 2026-02-26 |
| 2024-12-31 | $1.95M 10-K · filed 2026-02-26 |
| 2023-12-31 | $1.76M 10-K · filed 2026-02-26 |
| 2022-12-31 | $1.31M 10-K · filed 2025-02-27 |
| 2021-12-31 | $1.24M 10-K · filed 2024-02-22 |
| 2020-12-31 | $1.26M 10-K · filed 2023-02-23 |
| 2019-12-31 | $1.17M 10-K · filed 2022-02-24 |
| 2018-12-31 | $1.21M 10-K · filed 2021-02-25 |
| 2017-12-31 | $969.00K 10-K · filed 2020-02-27 |
| 2016-12-31 | $613.00K 10-K · filed 2019-02-27 |
| 2015-12-31 | $44.00K 10-K · filed 2018-03-07 |
| 2014-12-31 | $35.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |